On a behalf on an Italian company we are looking for new solutions in alternative to currently used anticoagulants to fight rodents (mice and rats).

Description of the Problem: We are looking for new solutions in alternative to currently used anticoagulants to fight rodents (mice and rats). More specifically, we are interested in identifying new substances to kill rodents. Anti-coagulant substances are currently the most used actives in rodenticides. However, growing concerns for the long-term viability of these substances make [...]

18 / 10 / 2016|News|

We have become coordinator of the PROGRESS-TT project

As of May 2, 2016, MITO Technology has become coordinator of PROGRESS-TT, an #H2020 project aimed at improving the transfer of technology from PROs to industry (www.progresstt.eu)

10 / 05 / 2016|News|

Microsoft acquires our client Solair

We are proud to report that our client Solair, a leading Italian company in the field of the Internet of Things led by Tom Davis, has been acquired by Microsoft. MITO was part of the legal and technical team involved in the acquisition and has dealt with the the intellectual property aspects related to the [...]

5 / 05 / 2016|News|

We are hiring!

This position is open as part of the coordination team of an on-going Horizon 2020 project. The position of Junior Project Administrator is structured as follows: 2 consecutive days per week at the premises of MITO Technology (Milano) From 01 May 2016 until 31 January 2018 The position includes the following key tasks: support to [...]

22 / 03 / 2016|News|

MITO Technology has assisted Nice S.r.l. in the successful transaction that led Amazon Web Services to acquire the company

MITO Technology, the leading strategic IP and licensing company in Italy, has assisted Nice S.r.l. in the successful transaction that led Amazon Web Services to acquire the company. Nice is an Italian SME, located in Asti, that gained a prominent position in the field of grid and cloud solutions. Nice and AWS will join forces [...]

7 / 03 / 2016|News|

Technology call: cardiovascolare

Per conto di una innovativa società tecnologica italiana, MITO Technology ricerca – con finalità di acquisizione o licenza – tecnologie brevettate nel settore cardiovascolare. Le tecnologie devono essere coperte da domanda di brevetto (con rapporto di ricerca) o brevetto concesso. Informazioni non confidenziali possono essere inviate, come manifestazione di interesse, a info@mitotech.eu

3 / 11 / 2015|News|

We are hiring!

MITO Technology seleziona una figura di giovane laureato da avviare alla carriera di junior technology transfer manager per la sede di Milano. L’assunzione è subordinata al superamento di un percorso di prova e formazione interna. Il candidato ideale è un laureato di qualsiasi nazionalità, con ottima conoscenza della lingua italiana e della lingua inglese. La [...]

2 / 10 / 2015|News|

PROGRESS TT Questionnaire TTO

The PROGRESS-TT project (PROs GRowing Europe through best practice SolutionS for Technology Transfer) is a three-year European Commission-funded Horizon 2020 project aiming at contributing to Europe’s economic growth by ensuring that Public Research Organisations (PROs) are better equipped to transfer valuable knowledge to industry (see leaflet attached). PROs include universities and public research institutes. The [...]

1 / 07 / 2015|News|

Progress-TT marching ahead with projects activities

Next meeting is schedule to take place in Leipzig at the Fraunhofer MOEZ Institute. Progress-TT is the name of the consortium that has been entrusted by the European Commission with a capacity building action for technology transfer offices at European research institutions (including universities and public research centers and hospitals) under the Access to Risk [...]

28 / 05 / 2015|News|

8th BioVaria to Take Place in Munich on 11 May 2015 – MITO Technology unveils first technology highlights

MITO Technology unveils first technology highlights: preparation of micro- or nanosystems based on inorganic oxides with controlled porosity for carrying biologically active or activable substances. BioVaria press release.pdf  (136 Kb)

26 / 03 / 2015|News|

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Per saperne di più o negare il consenso a tutti o ad alcuni cookie, consulta l' informativa estesa. Chiudendo questo banner, scorrendo la pagina, cliccando su qualsiasi link o comunque proseguendo la navigazione, acconsenti all’uso dei cookie.

Chiudi